Shares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been assigned a consensus rating of "Hold" from the eleven brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $3.03.
Several analysts have recently commented on BLUE shares. JPMorgan Chase & Co. downgraded shares of bluebird bio from a "neutral" rating to an "underweight" rating in a report on Friday, November 15th. Barclays lowered their price target on shares of bluebird bio from $4.00 to $2.00 and set an "overweight" rating on the stock in a report on Friday, November 15th. Bank of America lowered bluebird bio from a "buy" rating to a "neutral" rating and reduced their price objective for the company from $3.00 to $0.50 in a research note on Friday, November 15th. Royal Bank of Canada restated a "sector perform" rating and issued a $4.00 target price on shares of bluebird bio in a research note on Friday, November 15th. Finally, Wells Fargo & Company reduced their price target on bluebird bio from $3.00 to $2.00 and set an "equal weight" rating for the company in a research report on Wednesday, September 25th.
Read Our Latest Report on BLUE
A number of hedge funds and other institutional investors have recently made changes to their positions in BLUE. Allegheny Financial Group LTD acquired a new position in bluebird bio during the second quarter worth $25,000. Verition Fund Management LLC purchased a new stake in shares of bluebird bio during the third quarter worth about $42,000. Bayesian Capital Management LP acquired a new position in shares of bluebird bio during the 1st quarter worth about $52,000. SG Americas Securities LLC lifted its stake in bluebird bio by 152.4% in the 3rd quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock valued at $64,000 after buying an additional 74,185 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its holdings in bluebird bio by 113.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company's stock worth $71,000 after buying an additional 29,113 shares during the last quarter. Hedge funds and other institutional investors own 87.43% of the company's stock.
Shares of BLUE stock opened at $0.35 on Friday. The business has a fifty day moving average of $0.47 and a 200 day moving average of $0.77. bluebird bio has a 1 year low of $0.29 and a 1 year high of $5.53. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.51 and a quick ratio of 0.33. The firm has a market capitalization of $68.07 million, a price-to-earnings ratio of -0.19 and a beta of 0.76.
bluebird bio (NASDAQ:BLUE - Get Free Report) last released its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. bluebird bio had a negative return on equity of 322.46% and a negative net margin of 565.74%. The firm had revenue of $18.57 million for the quarter. As a group, research analysts expect that bluebird bio will post -1.35 earnings per share for the current year.
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider bluebird bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bluebird bio wasn't on the list.
While bluebird bio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.